financetom
Business
financetom
/
Business
/
DuPont raises full-year forecasts on strong electronics, AI-tech demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DuPont raises full-year forecasts on strong electronics, AI-tech demand
Jul 31, 2024 3:25 AM

Industrial materials maker DuPont de Nemours ( DD ) raised full-year forecasts on Wednesday, benefiting from strong demand for electronics and artificial intelligence-based technology that helped it beat second-quarter results.

After widely destocking last year due to low demand, an uptick in the manufacturing sector is benefiting companies that make chemicals and other materials used in a variety of industries including automotive and electronics.

Production at factories in the United States rose 1.1% in June from a year earlier, and climbed 3.4% in the second quarter.

DuPont's ( DD ) electronics and industrial unit, its biggest in terms of sales, saw a 7.1% rise in net sales in the quarter, driven by strong demand for semiconductors and consumer technology products.

CEO Lori Koch, who took the role in May, said the company had made progress around separating its electronics and water businesses.

DuPont ( DD ) announced plans to split its electronics and water segments in May, and said it expected to complete the process within 18-24 months.

The company on Wednesday raised its 2024 adjusted earnings forecast to $3.70 to $3.80 per share, from its previous range of$3.45 to $3.75, and net sales estimate to $12.40 billion and $12.50 billion, from $12.10 billion to $12.40 billion previously.

The Wilmington, Delaware-based company reported an adjusted profit of 97 cents per share for the second quarter, above analysts' average estimate of 85 cents, according to LSEG data.

(Reporting by Seher Dareen in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Meritage Homes Insider Bought Shares Worth $819,610, According to a Recent SEC Filing
Meritage Homes Insider Bought Shares Worth $819,610, According to a Recent SEC Filing
Feb 12, 2025
04:39 PM EST, 02/12/2025 (MT Newswires) -- Steven J Hilton, Director, Executive Chairman, on February 10, 2025, executed a purchase for 11,000 shares in Meritage Homes ( MTH ) for $819,610. Following the Form 4 filing with the SEC, Hilton has control over a total of 837,134 common shares of the company, with 25,942 shares held directly and 811,192 controlled...
Service International Q4 Earnings, Revenue Rise; Initiates 2025 Guidance
Service International Q4 Earnings, Revenue Rise; Initiates 2025 Guidance
Feb 12, 2025
04:39 PM EST, 02/12/2025 (MT Newswires) -- Service International (SCI) reported Q4 adjusted diluted earnings Wednesday of $1.06 per share, compared to $0.93 a year earlier. Analysts polled by FactSet expected $1.05. Revenue for the quarter ended Dec. 31 was $1.09 billion, up from $1.06 billion a year earlier. Analysts surveyed by FactSet expected $1.08 billion. The company said it...
TD Bank Group Closed Sale of Schwab Stock
TD Bank Group Closed Sale of Schwab Stock
Feb 12, 2025
04:41 PM EST, 02/12/2025 (MT Newswires) -- TD Bank Group announced after trade Wednesday it had closed the sale of its entire equity investment in The Charles Schwab Corporation , consisting of 184,678,738 shares in Schwab's common stock representing 10.1% economic ownership. The Bank sold 165,443,530 shares through a registered offering at a price of US$79.25 per share, and Schwab...
Ozempic shows some promise for alcohol use disorder
Ozempic shows some promise for alcohol use disorder
Feb 12, 2025
Feb 12 (Reuters) - Novo Nordisk's blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a small trial, researchers reported on Wednesday. The 48 participants in the nine-week trial all had moderately severe alcohol use disorder and were given either once-weekly Ozempic or a placebo. Ahead of the trial, they were invited to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved